english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Telithromycin (Ketek°): a welcome market withdrawal

The company's decision to withdraw this antibiotic from the market is good news for patients, in view of the drug's negative harm-benefit balance. It is a pity that the European Medicines Agency did not muster the courage to order withdrawal of this drug long before.
1 September 2018

Low back pain: no corticosteroids

There is no evidence that systemic corticosteroids have any efficacy on low back pain, beyond a placebo effect. Furthermore, they expose patients to numerous adverse effects.
1 September 2018

David Young: A translator who helped expand Prescrire's international reach

David Young, who died recently, was more than a highly professional translator; he was a faithful colleague and friend of Prescrire's editorial team.
1 September 2018

"Top Texts of 2018", new from the Editors of Prescrire International

 NEW: FREE SPECIAL EDITION  Check out this brand new sampling of texts selected by our Editors to introduce you to Prescrire International, a wholly independent monthly journal, written by and for healthcare professionals
1 September 2018

Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use

FEATURED REVIEW Given its weak efficacy and sometimes serious adverse effects, the harm-benefit balance of statin therapy in primary cardiovascular prevention is uncertain and close to neutral. Much else can be done to reduce cardiovascular risk via smoking cessation, physical activity and healthier eating habits.
Full review (8 pages) available for download by subscribers.
1 July 2018

In the July/August issue of Prescrire International: pembrolizumab (Keytruda°) in Hodgkin lymphoma with no further treatment options

FREE DOWNLOAD The immunostimulatory anti-PD-1 antibody pembrolizumab (Keytruda°) has been authorised in the European Union for patients with relapsed or refractory Hodgkin lymphoma, in spite of inadequate premarketing assessment.
Full text available for free download.
1 July 2018

Prescrire's review of drug packaging in 2017: some progress, but many risks remain

In 2017, unchallenged by overly lenient health authorities, a large number of pharmaceutical companies continued to launch, or to maintain on the market, drugs with dangerous packaging.
1 July 2018

Multiple sclerosis: a drug that should never have been authorised

In March 2018, after several deaths, daclizumab (Zinbryta°) was withdrawn from the market. The European Medicines Agency should never have authorised this drug.
1 July 2018

Drug prices, therapeutic value and access to medicines: civil society adds its voice to the debate in France, to defend the public interest

20 June 2018

Drugs for Alzheimer's disease: finally delisted in France!

The drugs available in mid-2018 for Alzheimer's disease have only minimal and transient efficacy. They have disproportionate, serious and sometimes fatal adverse effects. It is better to avoid them and to focus instead on reorganising the patient's daily life, keeping him or her active, and providing support and help for caregivers and family members.
15 June 2018

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90